Avita Medical (NASDAQ:RCEL) Earns "Buy" Rating from D. Boral Capital

Key Points

• Avita Medical's stock received a "buy" rating with a target price of $14.00 from D. Boral Capital, indicating a potential upside of 207.02% from its current price.
• Despite this positive outlook, Avita Medical has recently faced downgrades from other analysts, including a "sell" rating from BTIG Research with a $3.00 target price.
• The company reported a loss of ($0.38) earnings per share for the last quarter, missing estimates, and has a market cap of $121.39 million.

D. Boral Capital reissued their buy rating on shares of Avita Medical (NASDAQ:RCEL - Free Report) in a report issued on Monday morning,Benzinga reports. They currently have a $14.00 price objective on the stock.

A number of other research firms also recently weighed in on RCEL. Wall Street Zen downgraded shares of Avita Medical from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. BTIG Research lowered shares of Avita Medical from a "neutral" rating to a "sell" rating and set a $3.00 price target on the stock. in a research note on Friday, August 8th. Finally, Lake Street Capital reduced their price objective on shares of Avita Medical from $14.00 to $8.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $11.60.

Avita Medical Price Performance

NASDAQ RCEL traded down $0.08 on Monday, reaching $5.46. 142,925 shares of the stock traded hands, compared to its average volume of 389,035. The company has a market cap of $145.34 million, a price-to-earnings ratio of -2.77 and a beta of 1.58. Avita Medical has a 12 month low of $3.60 and a 12 month high of $14.16. The company has a quick ratio of 0.46, a current ratio of 0.58 and a debt-to-equity ratio of 9.39. The firm's fifty day simple moving average is $5.14 and its 200 day simple moving average is $6.66.

Avita Medical (NASDAQ:RCEL - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.12). Avita Medical had a negative return on equity of 632.62% and a negative net margin of 68.87%.The company had revenue of $18.42 million during the quarter, compared to analyst estimates of $34.27 million. Avita Medical has set its FY 2025 guidance at EPS. As a group, research analysts predict that Avita Medical will post -0.95 EPS for the current fiscal year.

Insider Activity

In related news, Director Robert Mcnamara bought 10,000 shares of the business's stock in a transaction that occurred on Thursday, August 28th. The stock was bought at an average cost of $4.50 per share, for a total transaction of $45,000.00. Following the completion of the transaction, the director owned 86,771 shares of the company's stock, valued at approximately $390,469.50. The trade was a 13.03% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders have acquired 24,000 shares of company stock worth $113,660. Insiders own 2.80% of the company's stock.

Hedge Funds Weigh In On Avita Medical

Several hedge funds have recently made changes to their positions in the business. Curi Capital LLC purchased a new position in Avita Medical during the 2nd quarter valued at $100,000. Bridgeway Capital Management LLC bought a new position in shares of Avita Medical during the second quarter valued at $199,000. Bank of America Corp DE grew its holdings in shares of Avita Medical by 49.7% in the second quarter. Bank of America Corp DE now owns 62,551 shares of the company's stock worth $331,000 after acquiring an additional 20,767 shares during the period. Jane Street Group LLC increased its position in Avita Medical by 36.1% in the second quarter. Jane Street Group LLC now owns 86,730 shares of the company's stock worth $459,000 after buying an additional 22,986 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Avita Medical during the 2nd quarter valued at about $58,000. 27.66% of the stock is owned by hedge funds and other institutional investors.

Avita Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.